Oscar Health (OSCR) Revenue & Revenue Breakdown
Oscar Health Revenue Highlights
Latest Revenue (Y)
$9.18B
Latest Revenue (Q)
$2.86B
Oscar Health Revenue by Period
Oscar Health Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $9.18B | 56.54% |
| 2023-12-31 | $5.86B | 42.11% |
| 2022-12-31 | $4.13B | 114.77% |
| 2021-12-31 | $1.92B | 225.78% |
| 2020-12-31 | $589.64M | 6.48% |
| 2019-12-31 | $553.78M | - |
Oscar Health generated $9.18B in revenue during NA 2024, up 56.54% compared to the previous quarter, and up 1657.26% compared to the same period a year ago.
Oscar Health Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $2.86B | -5.98% |
| 2025-03-31 | $3.05B | 27.31% |
| 2024-12-31 | $2.39B | -1.27% |
| 2024-09-30 | $2.42B | 9.20% |
| 2024-06-30 | $2.22B | 3.57% |
| 2024-03-31 | $2.14B | 49.68% |
| 2023-12-31 | $1.43B | -0.58% |
| 2023-09-30 | $1.44B | -5.40% |
| 2023-06-30 | $1.52B | 3.57% |
| 2023-03-31 | $1.47B | 41.63% |
| 2022-12-31 | $1.04B | 1.88% |
| 2022-09-30 | $1.02B | -3.76% |
| 2022-06-30 | $1.06B | 4.67% |
| 2022-03-31 | $1.01B | 94.32% |
| 2021-12-31 | $520.33M | 12.58% |
| 2021-09-30 | $462.19M | -15.93% |
| 2021-06-30 | $549.75M | 41.43% |
| 2021-03-31 | $388.69M | 107.16% |
| 2020-12-31 | $187.63M | 40.75% |
| 2020-09-30 | $133.31M | -8.43% |
| 2020-06-30 | $145.57M | 18.23% |
| 2020-03-31 | $123.13M | - |
Oscar Health generated $2.86B in revenue during Q2 2025, up -5.98% compared to the previous quarter, and up 133.65% compared to the same period a year ago.
Oscar Health Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BTSG | BrightSpring Health Services | $11.27B | $3.33B |
| OSCR | Oscar Health | $9.18B | $2.86B |
| BLCO | Bausch + Lomb | $4.77B | $1.27B |
| ALHC | Alignment Healthcare | $2.70B | $1.02B |
| ALKS | Alkermes | $1.56B | $394.19M |
| PTCT | PTC Therapeutics | $806.78M | $1.18B |
| GKOS | Glaukos | $383.48M | $124.12M |
| ACLX | Arcellx | $107.94M | $8.13M |
| ARWR | Arrowhead Pharmaceuticals | $3.55M | $542.71M |
| MTSR | Metsera | - | - |